Infantile Spasm (West Syndrome) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Infantile Spasm (West Syndrome) - Pipeline Review, H1 2016

Infantile Spasm (West Syndrome) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Infantile Spasm (West Syndrome) - Pipeline Review, H1 2016
Published May 31, 2016
55 pages — Published May 31, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Infantile Spasm (West Syndrome) - Pipeline Review, H1 2016, provides an overview of the Infantile Spasm (West Syndrome) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Infantile Spasm (West Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Infantile Spasm (West Syndrome) and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Infantile Spasm (West Syndrome)
- The report reviews pipeline therapeutics for Infantile Spasm (West Syndrome) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Infantile Spasm (West Syndrome) therapeutics and enlists all their major and minor projects
- The report assesses Infantile Spasm (West Syndrome) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Infantile Spasm (West Syndrome)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Infantile Spasm (West Syndrome)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeuti

  
Source:
Document ID
GMDHC8152IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Infantile Spasm (West Syndrome) Overview61
Therapeutics Development71
  Pipeline Products for Infantile Spasm (West Syndrome) Overview71
Infantile Spasm (West Syndrome) Therapeutics under Development by Companies81
Infantile Spasm (West Syndrome) Pipeline Products Glance92
  Clinical Stage Products91
  Early Stage Products101
Infantile Spasm (West Syndrome) Products under Development by Companies111
Infantile Spasm (West Syndrome) Companies Involved in Therapeutics Development125
  Anavex Life Sciences Corp.121
  Catalyst Pharmaceuticals, Inc.131
  INSYS Therapeutics, Inc.141
  Novartis AG151
  Retrophin Inc.161
Infantile Spasm (West Syndrome) Therapeutics Assessment179
  Assessment by Monotherapy Products171
  Assessment by Target182
  Assessment by Mechanism of Action202
  Assessment by Route of Administration222
  Assessment by Molecule Type242
Drug Profiles2610
  ANAVEX-273 - Drug Profile261
    Product Description261
    Mechanism of Action261
    R&D Progress262
  AVL-5189 - Drug Profile281
    Product Description281
    Mechanism of Action281
    R&D Progress281
  cannabidiol - Drug Profile291
    Product Description291
    Mechanism of Action291
    R&D Progress292
  cosyntropin - Drug Profile311
    Product Description311
    Mechanism of Action311
    R&D Progress311
  cosyntropin ER - Drug Profile321
    Product Description321
    Mechanism of Action321
    R&D Progress321
  CPP-115 - Drug Profile331
    Product Description331
    Mechanism of Action331
    R&D Progress333
Infantile Spasm (West Syndrome) Recent Pipeline Updates3611
Infantile Spasm (West Syndrome) - Dormant Projects471
Infantile Spasm (West Syndrome) Product Development Milestones486
  Featured News &Press Releases481
    May 18, 2016: Anavex Announces Positive Preclinical Data for ANAVEX 2-73 in Infantile Spasms481
    Feb 09, 2016: Insys Therapeutics Enrolls First Patient in Phase II Study for the Treatment of Infantile Spasms Using Pharmaceutical CBD481
    Dec 16, 2015: Catalyst Pharmaceuticals Announces Top-Line Results in Phase 1(b) Trial of CPP-115491
    Aug 04, 2015: Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol for the Treatment of Infantile Spasms491
    Nov 24, 2014: Catalyst Pharmaceuticals Announces Notice of Allowance of U.S. Patent Application for the Reduction or Elimination of Visual Field Defects by Treating Patients With CPP-115501
    Sep 02, 2014: Catalyst Pharmaceutical Partners Initiates Phase 1(b) Safety and Tolerance Study for CPP-115501
    Nov 18, 2013: Catalyst Pharmaceutical Partners Announces Publication of Preclinical Proof-of-Principle of CPP-115 Efficacy in Suppressing Infantile Spasms in Epilepsia511
    Feb 13, 2012: Catalyst Receives Orphan Medicinal Product Designation In EU For CPP-115 To Treat West Syndrome521
    Jan 31, 2012: Catalyst Pharmaceutical Partners To Present CPP-115 Progress At 2012 Epilepsy Pipeline Update Conference521
    Dec 15, 2011: Catalyst Announces Scientific Paper Regarding CPP-115 For Treatment Of Cocaine Addiction Accepted For Publication In Journal Of Medicinal Chemistry531
Appendix542
  Methodology541
  Coverage541
  Secondary Research541
  Primary Research541
  Expert Panel Validation541
  Contact Us541
  Disclaimer551

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Infantile Spasm (West Syndrome) - Pipeline Review, H1 2016" May 31, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Infantile-Spasm-West-Syndrome-Pipeline-Review-H1-2016-2088-15903>
  
APA:
Global Markets Direct - Market Research. (2016). Infantile Spasm (West Syndrome) - Pipeline Review, H1 2016 May 31, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Infantile-Spasm-West-Syndrome-Pipeline-Review-H1-2016-2088-15903>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.